Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 351
Gene Symbol: APP
APP
0.060 GeneticVariation disease BEFREE A double transgenic mouse expressing the amyloid precursor protein, bearing the Swedish mutations, and expressing tau protein containing three of the mutations present in frontotemporal dementia linked to chromosome 17 (FTDP-17), has been characterized. 15664690 2005
Entrez Id: 351
Gene Symbol: APP
APP
0.060 GeneticVariation disease BEFREE We describe a case of dementia clinically compatible with frontotemporal dementia in an APP Ala713Thr mutation carrier in which both [18F]Florbetapir PET uptake and Aβ1-42 cerebrospinal fluid levels were normal. 28304299 2017
Entrez Id: 351
Gene Symbol: APP
APP
0.060 GeneticVariation disease BEFREE The effects caused by these mutations strongly resemble those of pathological mutations of the AAA-ATPase p97 which cause the hereditary proteinopathy IBMPFD (inclusion body myopathy associated with Paget's disease of the bone and frontotemporal dementia). 28303975 2017
Entrez Id: 351
Gene Symbol: APP
APP
0.060 GeneticVariation disease BEFREE As amyloid-β levels increase with age even without amyloid precursor protein mutation, we suggest that this rise could contribute to age-related decline in frontotemporal dementia. 29729423 2018
Entrez Id: 10533
Gene Symbol: ATG7
ATG7
0.010 Biomarker disease BEFREE Together with our observation that ATG7 is reduced in ALS-FTD brain tissues, these findings identify the autophagy pathway as one key effector of nuclear depletion of TARDBP that contributes to neurodegeneration. 31242080 2020
Entrez Id: 498
Gene Symbol: ATP5F1A
ATP5F1A
0.010 Biomarker disease BEFREE C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. 31086314 2019
Entrez Id: 374868
Gene Symbol: ATP9B
ATP9B
0.100 GeneticVariation disease GWASCAT Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. 29724592 2018
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.060 Biomarker disease BEFREE Our study does not support a major role of ATXN2 intermediate CAG expansions in predisposing to FTD but suggests that ATXN2 may act as a phenotype modifier. 30342763 2019
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.060 Biomarker disease BEFREE The effects of intermediate ATXN2 repeats were most profound in probands with MND or FTD/MND (2.1% vs. 0% in control subjects, p = 0.013), whereas the frequency in probands with FTD was identical to control subjects. 24866401 2014
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.060 GeneticVariation disease BEFREE OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. 29080331 2018
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.060 GeneticVariation disease BEFREE For the ATXN2 gene, we observed an increase in IA frequency in AD cases (AD 4.1% vs. controls 1.8%) and in the behavioral FTD group (4.8% vs. 1.8%). 31810584 2020
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.060 Biomarker disease BEFREE Thus, we propose that excessive mislocalization of the RNA-binding proteins TDP-43, FUS, and ataxin-2 into the cytoplasm leads to impairment of the RNA quality control system, forming the core of the ALS/FTLD-U degenerative cascade. 21956718 2011
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.060 Biomarker disease BEFREE Furthermore, we propose that ATXN2 polyQ expansions could act as a strong modifier of the FTD phenotype in the presence of a C9orf72 repeat expansion, leading to the development of clinical signs featuring both FTD and ALS. 25098532 2014
Entrez Id: 8314
Gene Symbol: BAP1
BAP1
0.010 GeneticVariation disease BEFREE Furthermore, ubiquitin carboxy terminal hydrolase L1 gene is responsible for an autosomal dominant form of typical PD, although only a single family has so far been identified with a mutation of this gene, and tau has been identified as a causative gene for frontotemporal dementia and parkinsonism. 11205133 2000
Entrez Id: 590
Gene Symbol: BCHE
BCHE
0.030 GeneticVariation disease BEFREE We analyzed APOE and BuChE polymorphisms in 167 AD and 59 fronto-temporal dementia (FTD) patients compared with 129 healthy controls (HC). 20058037 2010
Entrez Id: 590
Gene Symbol: BCHE
BCHE
0.030 Biomarker disease BEFREE Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). 28103749 2017
Entrez Id: 590
Gene Symbol: BCHE
BCHE
0.030 Biomarker disease BEFREE Current antidementia drugs, including cholinesterase inhibitors and memantine, have no consistent positive effects in FTD. 25059437 2014
Entrez Id: 662
Gene Symbol: BNIP1
BNIP1
0.010 GeneticVariation disease BEFREE BNIP1 expression was significantly reduced in spinal cord motor neurons from patients with ALS (4 controls: mean age, 60.5 years, mean [SE] value, 3984 [760.8] arbitrary units [AU]; 7 patients with ALS: mean age, 56 years, mean [SE] value, 1999 [274.1] AU; P = .02), in an ALS mouse model (mean [SE] value, 13.75 [0.09] AU for 2 SOD1 WT mice and 11.45 [0.03] AU for 2 SOD1 G93A mice; P = .002) and in brains of patients with PSP (80 controls: 39 females; mean age, 82 years, mean [SE] value, 6.8 [0.2] AU; 84 patients with PSP: 33 females, mean age 74 years, mean [SE] value, 6.8 [0.1] AU; β = -0.19; P = .009) or FTD (11 controls: 4 females; mean age, 67 years; mean [SE] value, 6.74 [0.05] AU; 17 patients with FTD: 10 females; mean age, 69 years; mean [SE] value, 6.53 [0.04] AU; P = .005). 29630712 2018
Entrez Id: 140683
Gene Symbol: BPIFA2
BPIFA2
0.030 Biomarker disease BEFREE Frontotemporal dementia (FTD) refers to a disease spectrum including the behavioral variant FTD (bvFTD), primary progressive aphasia (PPA), progressive supranuclear palsy/corticobasal degeneration syndrome (PSP/CBDS), and FTD with amyotrophic lateral sclerosis (FTD-ALS). 23254636 2013
Entrez Id: 140683
Gene Symbol: BPIFA2
BPIFA2
0.030 Biomarker disease BEFREE Atrophy colocated with cerebellar areas implicated for motor (PSP, MSA) or cognitive symptoms (FTD, ALS, PSP) in the diseases. 28501823 2017
Entrez Id: 140683
Gene Symbol: BPIFA2
BPIFA2
0.030 GeneticVariation disease BEFREE Over two dozen mutations in the gene encoding the microtubule associated protein tau cause a variety of neurodegenerative dementias known as tauopathies, including frontotemporal dementia (FTD), PSP, CBD and Pick's disease. 24086739 2013
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.010 Biomarker disease BEFREE In this study, we examined the immunohistochemical distribution of BRCA1 and another DDR protein, p53-Binding Protein 1 (53BP1), in AD, Pick disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration, and frontotemporal dementia with parkinsonism linked to chromosome 17. 31750914 2020
Entrez Id: 56244
Gene Symbol: BTNL2
BTNL2
0.110 Biomarker disease BEFREE A recent large genome-wide association study reported several single nucleotide polymorphisms (SNPs) at the RAB38, RAB38/CTSC, HLA-DRA/HLA-DRB5, and BTNL2 in association with FTD. 26967218 2016
Entrez Id: 56244
Gene Symbol: BTNL2
BTNL2
0.110 GeneticVariation disease GWASDB Frontotemporal dementia and its subtypes: a genome-wide association study. 24943344 2014
Entrez Id: 203228
Gene Symbol: C9orf72
C9orf72
0.500 GeneticVariation disease BEFREE A pathogenic hexanucleotide repeat expansion within the C9orf72 gene has been identified as the major cause of two neurodegenerative syndromes, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 28522837 2017